This website is intended for UK healthcare professionals only
User log in




Trial log in
  

MULTI DRUG RESISTANCE

Multi drug resistant (MDR) micro-organisms that resist the action of antimicrobial drugs (antibiotics). This is a critically important issue as it can make the treatment of infections more difficult and increase hospital costs. Increasing numbers of infections are developing that cannot be treated, and many existing antimicrobial agents are becoming less effective. In addition, the development of new anitbiotics is at an all time low.

In a few instances, micro-organisms are naturally resistant to antimicrobial drugs, but a more common problem is when a micro-organism that is naturally susceptible to the action of particular antimicrobial agents develops resistance. The problem is attributed to excessive use of antibiotics, which eliminate competing susceptible micro-organisms allowing the resistant strains to proliferate.

Examples of antimicrobial resistant organisms include methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus, Enterococcus, Pseudomonas aeruginosa, Clostridium difficile, Mycobacterium tuberculosis[italics] and others.

Public Health England and NICE. Managing common infections: guidance for primary care https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care

Department of Health and Social Care. UK 20-year vision for antimicrobial resistance; 2019 https://www.gov.uk/government/publications/uk-20-year-vision-for-antimicrobial-resistance   

Treat Antibiotics Responsibly, Guidance and Education Tool (TARGET) – toolkit for general practice https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit.aspx

MRSA (methicillin-resistant Staphylococcus aureus)

Gram-positive bacterium that can occur on skin and inside the nostrils in healthy individuals. If it invades the body, MRSA can cause septicaemia, pneumonia, osteomyelitis and endocarditis. Detected in 1961, MRSA is spread by skin-to-skin contact and is resistant to common antibiotics.

NHS. MRSA Infection; updated 2020  https://www.nhs.uk/conditions/mrsa/
Public Health England. Staphylococcus aureus: guidance, data and analysis; 2014 (updated 2020) https://www.gov.uk/government/collections/staphylococcus-aureus-guidance-data-and-analysis
NICE NG15. Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use; 2015 https://www.nice.org.uk/guidance/ng15
NICE has published around 20 guidelines on antimicrobial prescribing in individual conditions, with the aim of reducing inappropriate prescribing and reducing the spread of antibiotic-resistant infections. See https://www.nice.org.uk/guidance/published?type=apg

NDM-1

In late August 2010 Lancet Infectious Diseases reported a new type of ‘superbug’ resistant to the carbapenem antibiotics used on hard-to-treat infections such as MRSA. Resistance is conferred by the NDM-1 (New Delhi metallo-ß-lactamase-1) enzyme, which is capable of destroying antibiotics and can be transferred between types of bacteria leading to acquired antimicrobial resistance. It is most often seen in the Gram-negative bacteria E. coli and Klebsiella pneumoniae.

Bacteria with the NDM-1 mutation have been found in UK patients recently returned after receiving medical treatment in India and Pakistan, where resistance has become increasingly common. Infections have been mild to severe, some have been fatal. Similar infections have occurred in the USA, Canada, Australia and the Netherlands. Most work on new antibiotics is with Gram-positive organisms such as MRSA, and international researchers say that NDM-1 could become a major global health problem.

Return to index